1.57

1.29% +0.02

After Hours: 1.5884 0.0184 +1.17%

Iterum Therapeutics Plc (ITRM)

Overview News Price History Why ITRM Down? Discussions Forecast Stock Split

Iterum Therapeutics Plc stock is currently priced at $1.57, with a 24-hour trading volume of 50,845. It has seen a +1.29% increased in the last 24 hours and a +1.29% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.55 pivot point. If it approaches the $1.60 resistance level, significant changes may occur.

Previous Close:

$1.55

Open:

$1.52

24h Volume:

50,845

Market Cap:

$25.05M

Revenue:

Net Income/Loss:

$-31.10M

P/E Ratio:

-0.3473

EPS:

-4.52

Net Cash Flow:

$-30.81M

1W Performance:

+9.79%

1M Performance:

+1.29%

6M Performance:

+141.50%

1Y Performance:

+53.17%

1D Range:

$1.50

$1.57

52W Range:

$0.622

$2.50

Iterum Therapeutics Plc Stock (ITRM) Company Profile

Name

Iterum Therapeutics Plc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

353 1 669 4820

Address

Fitzwilliam Court, 1st Floor Leeson Close, Dublin

Employee

Twitter

Next Earnings Date

2024-05-10

Latest SEC Filings

ITRM's Discussions on Twitter

Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-28-21	Upgrade	Gabelli & Co	Sell → Hold
Mar-15-21	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-02-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jan-21-20	Downgrade	Gabelli & Co	Buy → Sell
Dec-11-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-21-19	Initiated	H.C. Wainwright	Buy

View All

Iterum Therapeutics Plc Stock (ITRM) Latest News

Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

GlobeNewswire Inc.

Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat

GlobeNewswire Inc.

Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up

Zacks Investment Research

Insiders Buying Iterum Therapeutics And 3 Other Stocks Under $3

Benzinga

Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023

GlobeNewswire Inc.

Iterum Therapeutics Plc Stock (ITRM) Financials Data

Iterum Therapeutics Plc (ITRM) Net Income 2024

ITRM net income (TTM) was -$31.10 million for the quarter ending September 30, 2023, a +28.55% increase year-over-year.

Iterum Therapeutics Plc (ITRM) Cash Flow 2024

ITRM recorded a free cash flow (TTM) of -$30.81 million for the quarter ending September 30, 2023, a -84.52% decrease year-over-year.

Iterum Therapeutics Plc (ITRM) Earnings per Share 2024

ITRM earnings per share (TTM) was -$2.44 for the quarter ending September 30, 2023, a +24.92% growth year-over-year.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.